 SAN DIEGO, May 28, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation NASDAQ: ADMP, a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose the Company, today announced that, as expected, on May 25, 2021, it received a standard notification letter the Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC NASDAQ notifying the Company that, because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 the Filing or the Form 10-Q, the Company is no longer in compliance with NASDAQ Marketplace Rule 5250c1, which requires timely filing of periodic reports with the Securities and Exchange Commission the SEC. 